Journal article
Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario
Abstract
Rituximab is the first antibody-based therapy approved in cancer. The role of this treatment for non-Hodgkin's lymphoma has evolved significantly since its introduction. We aimed to systematically review the literature on rituximab in non-Hodgkin's lymphoma and provide consensus guidelines as to the rational use of this agent. Validated methodology from the Cancer Care Ontario Program in Evidence-Based Care was applied. A comprehensive …
Authors
Cheung MC; Haynes AE; Meyer RM; Stevens A; Imrie KR; Care the Members of the Hematology DSGOTCCOPIE-B
Journal
Cancer Treatment Reviews, Vol. 33, No. 2, pp. 161–176
Publisher
Elsevier
Publication Date
April 2007
DOI
10.1016/j.ctrv.2006.10.005
ISSN
0305-7372